KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash & Equivalents (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Cash & Equivalents for 17 consecutive years, with $529.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 8.54% to $529.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $529.8 million through Dec 2025, up 8.54% year-over-year, with the annual reading at $529.8 million for FY2025, 8.54% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $529.8 million at Bio-Rad Laboratories, up from $395.8 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $859.9 million in Q3 2021, with the low at $369.3 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $517.9 million, with a median of $467.5 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents tumbled 42.15% in 2023, then increased 20.88% in 2024.
  • Over 5 years, Cash & Equivalents stood at $470.8 million in 2021, then fell by 7.77% to $434.2 million in 2022, then decreased by 7.0% to $403.8 million in 2023, then grew by 20.88% to $488.1 million in 2024, then increased by 8.54% to $529.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $529.8 million, $395.8 million, and $369.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.